MedDataX Logo

The Performance of Cancer Risk Genes in the Necessity of Secondary TURBT

NCT ID: NCT05112523

Last Updated: 2021-11-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-20

Study Completion Date

2023-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators performed the Genetron Uro V1 test on the urine of patients before secondary TURBT and compared it with the final pathological results. To analyze the performance of the Genetron Uro V1 method in a study to predict the need for secondary TURBT in high-risk NMIBC patients and the correlation with patient's RFS and OS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The standard of treatment for patients with non-muscle invasive bladder cancer (NMIBC) is transurethral resection of bladder tumors (TURBT), with postoperative intravesical irrigation treatment options determined by the risk of recurrence. After TURBT surgery, tumor remnants are one of the most important causes of postoperative tumor recurrence. Studies have shown that secondary TURBT can detect residual bladder tumor lesions, obtain more accurate pathological staging, increase recurrence-free survival, improve patient prognosis, and enhance treatment outcomes. Current bladder cancer treatment guidelines recommend secondary TURBT for patients with (1) inadequate first TURBT (2) no muscle tissue in the first TURBT specimen, except for TaG1 and carcinoma in situ (3) stage T1 tumors (4) grade G3 tumors, except for carcinoma in situ. However, at present, the lack of screening methods for the population benefiting from secondary TURBT in clinical practice has led to some patients inevitably receiving overtreatment, increasing patient suffering, and financial costs, and raising the burden of government healthcare.

The genetic test for uroepithelial tumor risk (Genetron Uro V1) is a non-invasive liquid biopsy method based on urine samples, which has high diagnostic efficacy in patients with primary uroepithelial cancer. Investigators performed the Genetron Uro V1 test on the urine of patients before secondary TURBT and compared it with the final pathological results.

To analyze the performance of the Genetron Uro V1 method in a study to predict the need for secondary TURBT in high-risk NMIBC patients and the correlation with patient's RFS and OS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Bladder Cancer TURBT Liquid biopsy Uroepithelial cancer risk genes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with a confirmed diagnosis of high-risk NMIBC at each study center:

including (1) inadequate first TURBT; (2) absence of muscle tissue in the first TURBT specimen, except for TaG1 and carcinoma in situ alone; (3) stage T1 tumors; (4) grade G3 tumors, except for carcinoma in situ alone; (5) TaG1G2 meeting both multiple, recurrent, and \>3 cm in diameter (or low-grade urothelial epithelial carcinoma)
2. gender is not limited.
3. age ≥ 18 years old.
4. the ability to provide a 100 ml standing urine sample within 3-6 weeks after the first TURBT and before the secondary transurethral resection.
5. agree to provide basic personal clinical information and pathological and imaging data for use in scientific research and sign an informed consent form related to scientific research.
6. consent to perform the genetic testing services involved in the trial.
7. agree to provide monitoring results in the follow-up relapse monitoring process.

Exclusion Criteria

1. patients with other non-uroepithelial malignancies (including prostate cancer and renal cell carcinoma).
2. patients who failed to undergo secondary transurethral resection.
3. patients with incomplete information on sample pathology.
4. patients with contaminated samples.
5. Patients whose urine samples fail quality control and cannot be re-sampled for valid reasons.
6. Patients whose samples cannot complete the test due to reasonable cause.
7. any condition that, in the opinion of the investigator, may harm the subject or cause the subject to be unable to meet or perform the requirements of the study.
8. Patients who are unable to provide written informed consent.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hangzhou Jichenjunchuang Medical Laboratory Company

UNKNOWN

Sponsor Role collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Qiang Lv, MD，PHD

Role: PRINCIPAL_INVESTIGATOR

The First Affiliated Hospital with Nanjing Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The first affiliated hospital of Nanjing Medical University

Nanjing, Jiangsu, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lingkai Cai

Role: CONTACT

Phone: +86 15206213500

Email: [email protected]

Qiang Lv, MD，PHD

Role: CONTACT

Phone: +86 13505196501

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Qiang Lu, PhD

Role: primary

Xiao Yang

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-SR-277

Identifier Type: -

Identifier Source: org_study_id